Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Guidance Maintained For 30% Growth In 2022
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
You may also be interested in...
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.